
PROSION
Life science startup PROSION has found an innovative way to form potential drugs against a variety of hard-to-treat diseases from modular building blocks – addressing targets that are so far considered as undruggable.
Founded:
- Address: Luxemburger Strasse 53
- Zip/Postcode:
- City: Cologne
- Country: DE
- Mail: mutlu.yoenel@prosion.io
- Phone: +4915730338800
- Contact person for business: Mutlu Yönel
- Contact person for science: Slim Chiha
Company summary
PROSION established a toolkit of Proline-derived modules (ProMs), which can be combined into effective drugs for the above mentioned undruggable targets – finally making them druggable.
Technology field
Pharmaceutical & drug discovery start-up | Healthcare | Life Scienc
Technology and USP
PROSION established a toolkit of new and patented pharmaceutical building blocks, which can be effectively assembled into potential drugs for disease-related, undruggable targets – finally making them druggable. The innovative building blocks (ProMs) represent the world’s first peptidomimetics of the PPII-helix and were used in an initial proof-of-concept, to successfully address a particularly difficult target, that plays a key role in cancer metastasis – yet considered as undruggable.
Development until now
An A-team, consisting of scientists and entrepreneurs, with the support of highly experienced executive leaders, aims to exploit the value & potential of ProM building blocks through the following two streams:
– Stream I: The commercialization of the ProM toolkit for pharmaceutical companies and academia, enabling them to pursue independent research on (undruggable) targets.
– Stream II: The development of ProM-based lead compounds either for drug discovery or biomedical research in collaboration with key partners (corporates or academia).
Capital requirements:
PROSION ’s financial year 2020 is funded by two public grants for innovation. A €1.1 million funding will be required as of 2021 – mainly to finance the on-going oncological drug discovery projects.
Founder

Slim Chiha
– Slim is responsible for scientific development and strategic management.
– PhD in Cologne (Organic Chemistry) and training at Bayer HealthCare AG.
– Experience in organic synthesis (ProM-scaffolds), drug discovery and lead optimization (ENA/VASP Inhibitors).